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Background: Beneficial effects of early palliative care have been found in advanced cancer but the 
evidence is not unequivocal. 
Aim: To investigate the effect of early specialised palliative care (SPC) among advanced cancer 
patients identified in oncology departments. 
Setting/participants: The Danish Palliative Care Trial (DanPaCT; ClinicalTrials.gov 
NCT01348048) is a multicentre randomised clinical trial comparing early referral to a SPC team 
plus standard care versus standard care alone. The planned sample size was 300. At five oncology 
departments, consecutive patients with advanced cancer were screened for palliative needs. Patients 
with scores exceeding a predefined threshold for problems with physical, emotional or role 
function, or nausea/vomiting, pain, dyspnoea or lack of appetite according to the EORTC QLQ-C30 
questionnaire were eligible. The primary outcome was the change in each patient’s primary need 
(the most severe of the seven QLQ-C30 scales) at 3 and 8 weeks follow-up (0-100 scale). Five 
sensitivity analyses were conducted. Secondary outcomes were change in the seven QLQ-C30 
scales and survival.  
Results: Totally 145 patients were randomised to early SPC versus 152 to standard care. Early SPC 
showed no effect on the primary outcome of change in primary need (-4.9 points (95% confidence 
interval -11.3 to +1.5 points); p=0.14). The sensitivity analyses showed similar results. Analyses of 
the secondary outcomes, including survival, also showed no differences; maybe with the exception 
of nausea/vomiting where early SPC might have had a beneficial effect.  
Conclusion: We did not observe beneficial or harmful effects of early SPC, but important 
beneficial effects cannot be excluded.  
 
 






What is already known about the topic? 
• We searched PubMed using the terms ‘palliative care’ and ‘randomized controlled trial’ and 
‘quality of life’ and ‘cancer’. Studies investigating palliative care at the end of life were 
excluded.  
• Three individual-patient randomised controlled trials (RCT) and one cluster RCT investigating 
early multidisciplinary specialist palliative care (SPC) and three RCTs of advanced practiced 
nurses (one with an initial specialist palliative care assessment ) providing or coordinating early 
palliative care were identified.  
• Taken together, these trials indicate that early SPC may improve the patients’ quality of life, 
symptoms, survival and caregiver outcomes, but in several cases no effect of the interventions 
could be found. 
 
What this paper adds 
• Following an Italian trial restricted to pancreatic cancer patients this is the first European RCT 
investigating early SPC in patients with a range of diagnoses. The trial recruited advanced 
cancer patients from oncology departments in Denmark.  
• Patients with palliative care needs according to a screening instrument were randomised 
between SPC (i.e., referral to a palliative care team) plus standard care versus standard care 
alone.  
• We found no effect of SPC on the primary outcome or the secondary outcomes, including 




• Possible explanations of the lack of positive effect are suggested: the intensity of early SPC 
provided in this trial may have been insufficient because the SPC teams had not developed a 
model for the new target group, other patients with more acute needs may have been prioritised, 
and there may have been compensation in the control group. Alternatively, previous 
observations may have been biased or due to random errors. 
 
Implications for practice, theory or policy 
• Integration of specialised palliative care with oncology care has the potential to improve quality 
of life during the treatment of advanced cancer, lead to more patient-centred care, and 
potentially even increase survival. The American Society of Clinical Oncology (ASCO) has 
recommended implementation of early SPC.  
• The present RCT highlights the importance of carefully testing promising new health-care 
interventions in new settings.  
• Future research is needed to clarify how to design effective early SPC in various health care 
systems: which components of early SPC are effective for which patient groups at which points 
in the trajectory, and what is the best distribution of roles and responsibilities between SPC 





Palliative care aims to improve quality of life (QoL) by alleviating symptoms and problems. 1 
Specialised palliative care (SPC) is provided by health care professionals whose main task is to 
provide palliative care.  
 
In Denmark, referral to SPC is late: the median survival from first contact with SPC is only six 
weeks (96% of these patients had cancer).2 Many patients with advanced cancer have complex 
symptoms or problems long before being in their terminal phase,3-6 and the World Health 
Organization (WHO) recognises that SPC is applicable early in the disease trajectory.7  
 
A recent systematic review with meta-analysis identified forty-three randomised clinical trials 
(RCTs) investigating palliative care interventions in adults with life-limiting illness, and found 
improvements in QoL and symptom burden.8 Six North American trials have investigated the effect 
of early SPC in advanced cancer.1,9-13 Three trials tested access to an integrated palliative care 
service versus no access to this service.1,9,13 Temel and colleagues found improved QoL and mood 
after 12 weeks and prolonged survival in 151 newly diagnosed lung cancer patients.9 A subsequent 
study from the same group found no effect of early SPC on QoL at 12 weeks but a positive effect at 
24 weeks in 350 patients with lung or gastrointestinal cancer.13 Zimmermann and colleagues’ 
cluster-randomised trial included 461 advanced cancer patients and found no effect on the primary 
outcome (QoL at three months), but positive effects on some secondary outcomes including QoL 
and patient satisfaction mainly after four months.1  
Three trials were coordinated by advanced practice nurses. One trial (N=322) investigated a 
psycho-educational palliative care intervention versus usual care in 322 patients and found positive 
effects on QoL and depressed mood during one year.11,14 A subsequent trial (N=207) used a fast-
track design (30-60 days after diagnosis versus 3 months later) testing a slightly modified 
intervention including an initial SPC consultation  and found no effects on patient-reported 
outcomes but better 1-year survival10 and lower caregiver depression scores.15 A third cluster-
randomised trial (N=146) compared a multidisciplinary intervention coordinated by an advanced 
care nurse to enhanced usual care (a manual on symptom management) and found no effect on 
patient-reported outcomes.12 Recently, an Italian trial compared systematic versus on-demand early 
SPC in 207 pancreatic cancer patients and found improved QoL at 12 weeks.16 Thus, overall, the 
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findings about early SPC are mixed. The American Society of Clinical Oncology (ASCO) 
recommends early SPC.17,18  
 
In Denmark, a large, nationally representative survey of patients with advanced cancer, who had not 
been in contact with SPC, showed a high prevalence of palliative care needs.3,4 Based on these 
findings, the Danish Palliative Care Trial (DanPaCT) was designed to investigate the potential 
impact of early SPC in patients with advanced cancer and palliative care needs. The DanPaCT 
protocol and statistical analysis plan have been published.19,20 This article reports the primary and 




Palliative care in Denmark (5.7 million inhabitants) may take place in primary care, in hospital 
departments not specialised in palliative care (e.g., oncological), or in SPC centres. In 2011, SPC in 
Denmark consisted of 26 hospital-based palliative care teams/units and 17 hospices.2 Almost all 




This was a randomised clinical, multicentre, parallel-group superiority trial with balanced 
randomisation (1:1) conducted at six Danish SPC centres. The protocol was approved by the Ethics 
Committee for the Capital Region, Denmark (H-3-2010-144), the Danish Data protection agency 
(BBH-2011-05), and registered at www.clinicaltrials.gov (NCT01348048). 
 
The protocol has been described in detail elsewhere.19 Patients were randomised to the intervention 
group who were referred to a multi-disciplinary SPC team (further information about the teams in a 
prior publication19) plus standard care versus the control group who received standard care. In both 
groups standard care potentially included palliative care provided by the departments of oncology, 
general practitioners (GPs), or home care services. .  The trial period was eight weeks. 
Assuming a difference of 7.5 point in the primary outcome, the planned sample size was 300 (alpha 





The DanPaCT intervention consisted of ‘early SPC’ defined as ‘usual SPC’ initiated at an earlier 
time than would otherwise have been the case. Patients in the intervention group were referred to an 
SPC team, and the number and frequency of contacts with the SPC team and the treatments and 
other interventions were determined by the patient’s needs, following the European Association for 
Palliative Care White Paper21, the WHO guidelines7 and national and local guidelines. The common 
understanding was that SPC is a complex and multidisciplinary intervention that is adapted to each 
patient. No additional guidelines were developed for the intervention in DanPaCT since the SPC 
teams were expected to use the guidelines and expertise they already had. Likewise, procedures, 
activities, and processes were those normally used by the SPC teams and the interventions were 
given by the staff normally providing the interventions. The same was true for the location and 
timing of the treatment. The number of contacts between the SPC units and the included patients, 
the type of contacts, and the type of staff involved will be described in the Results section. After the 
completion of the eight weeks trial period patients remained in contact with the SPC team if 
clinically relevant according to the same principles as for other patients. Future research will 
investigate the activities and interventions reported in medical records in more detail based on 
qualitative analysis. Intervention fidelity was not assessed since there was not a specific manual for 
the intervention. No known modifications to the intervention happened over time.  
 
Patients 
Consecutive patients who were in oncological treatment or follow-up at five different departments 
of oncology were screened for palliative care needs by research nurses if they  
- had cancer stage IV22 or cancer in the central nervous system grade III/IV;  
- were ≥ 18 years;  
- lived in the area of one of the participating SPC centres;  
- had no contact with an SPC during the previous year.  
 
Patients were screened with the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30)23,24 and were eligible for the trial if they: 
a) Scored at least 50% of the score representing maximal symptom or maximally reduced 
functioning on at least one of the following seven scales: physical function, role function, 
emotional function, nausea and vomiting, pain, dyspnoea, or lack of appetite;  
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b) Had at least four additional symptoms (defined as a score of at least 33% of the score 
corresponding to maximal symptom burden or maximally reduced functioning) as measured by 
any of the 13 remaining scales (global health status/quality of life excluded). 
 
Among the seven EORTC QLQ-C30 scales listed in (a), the scale having the highest score at 
baseline was named as the patient’s ‘primary need’. 
 
Patients were excluded from the trial if they did not understand Danish well enough to fill in a 
questionnaire or were considered incapable of complying with the trial protocol.  
 
Randomisation and masking 
Central randomisation via telephone was carried out by the Copenhagen Trial Unit (CTU), which 
was independent of the trial administration office. The allocation sequence was computer-generated 
1:1 with varying block size of 8 and 12 per strata and was kept unknown for all investigators. 
Randomisation was stratified by ’primary need’. 
 
All statistical analyses of the primary and secondary outcomes were carried out blinded to 
intervention allocation. Based on blinded results, two conclusions concerning results for the primary 
and secondary outcomes were written down and agreed upon among authors before de-blinding.25,26 
 
Patient reported outcomes 
Patients received a questionnaire at baseline and at three and eight weeks follow up including the 
EORTC QLQ-C3023 and additional instruments.19   
 
The EORTC QLQ-C30 assesses health-related quality of life within the previous week. Scores 
ranging from 0 to 100 were estimated according to the scoring manual.24 Seven of the 15 scales 
(physical function, role function, emotional function, nausea/vomiting, pain, dyspnea, lack of 
appetite) were selected as key targets of palliative care by the palliative care physicians involved in 
the trial and constituted the primary and secondary outcomes of DanPaCT.20 For the analyses of the 




The primary outcome of DanPaCT was the change in the patient’s primary need. The primary 
outcome was thus a patient-individualised outcome, i.e., for a patient having the highest score for 
pain, the change in pain represented the primary outcome. 
 
The secondary outcomes were the changes in the seven QLQ-C30 scales; the analysis of each scale 
included all participants. 
	
Statistical analyses of the primary outcome 
All analyses were two-sided and were made with SAS statistical software version 9.3.27  
 
According to the statistical analysis plan (SAP),20 each outcome was estimated as the change from 
baseline to the weighted mean of the three- and eight-weeks follow-up measured as area under the 
curve (AUC). The analyses were adjusted for the stratification variable (primary need). All 
outcomes were normally distributed and multiple linear regressions were used. 
 
For the analysis of the primary outcome the significance level was 0.05, and a modified intention-
to-treat (ITT) analysis was conducted: patients who withdrew consent after randomization, were 
randomized but did not fulfil inclusion criteria, or died before eight weeks were excluded (Figure 
1). Missing answers were replaced using multiple imputations as described elsewhere.20 
 
Five sensitivity analyses were made: 
1) A fully adjusted analysis conducted as the primary analysis but additionally adjusted for the 
following covariates if they were significantly associated (p < 0.10) with the outcome: centre, 
WHO Performance Status, time since the patient was diagnosed with advanced disease, 
treatment status, sex, age, diagnosis, and education. 
2) A complete case analysis conducted as the primary analysis, but only including patients who 
had completed all three assessments (no imputation). 
3) Analysis of repeated measurements to investigate whether there was a difference in the 
intervention effect at the three- and eight-week follow-up.  
4) A per protocol analysis where patients in the intervention group who had not had contact with 
SPC were included in the control group, and patients in the control group who had contact with 
an SPC were included in the intervention group.  
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5) A full ITT analysis including all randomized patients except those who withdrew consent or did 
not fulfil inclusion criteria.  
 
Multiple imputations were conducted except in analysis 2. All analyses were adjusted for the 
primary need. 
 
Statistical analyses of the secondary outcomes 
The analyses of the seven scales from the EORTC QLQ-C30 were carried out as described for the 
primary outcome. Additionally, the same five sensitivity analyses were conducted.  
 
Survival was analysed using a Kaplan-Meier plot. Patients who were alive three months after the 
end of data collection (20 June 2014) were censored at this date. A Cox regression analysis was 
conducted adjusting for the primary need. One sensitivity analysis was made additionally adjusting 
for the covariates in the fully adjusted sensitivity analysis for the primary outcome.  
 






Patients were included from May 2011 to December 2013, and the last follow-up questionnaire was 
mailed in March 2014. A flow-chart of randomised patients can be seen in Figure 1. After screening 
for palliative care needs, 464 were considered eligible, and 306 patients were randomised, however, 
nine of them withdrew consent or were ineligible for the trial according to inclusion criteria and 
were therefore excluded from the analyses. Of the remaining 297 patients, 145 were allocated to the 
intervention group and 152 to the control group. Before the eight-week follow-up 15 patients died 
in each group (10% versus 10%), leaving 267 patients for the primary outcome analysis. The 
numbers of patients answering the three- and eight-week follow-up questionnaires were 247 and 
226, respectively.      
 




The characteristics of participants can be seen in Table 1. The majority of patients were 60 to 79 
years old, more were female and about one third had lung cancer. The majority were receiving 
chemotherapy when entering the trial, and almost two thirds had been diagnosed with advanced 
cancer within the previous year.   
 
The most frequent primary outcomes were role function (36%), dyspnoea (17%), and lack of 
appetite (16%). 
 
(Table 1 about here) 
 
Contact with the SPC team 
Of the 145 patients randomised to SPC, 138 had at least one face-to-face contact with the SPC team 
during the eight weeks trial period but only 74 patients had two or more face-to-face contacts (Table 
2). Most patients had additional telephone contacts, and 27 had more than five calls. In the control 
group, 13 patients had at least one face-to-face contact with the SPC team within the eight weeks. 
 
 (Table 2 about here) 
 
The primary outcome 
Early SPC had no significant effect on the primary outcome over 8 weeks (defined as AUC 
difference in symptoms equivalent to -4.9 points (0-100 scale); P=0.14) (Table 3). The 95% 
confidence interval was -11.3 to +1.5 points. The five sensitivity analyses showed similar results 
(Table 4).  
 
Both groups had relatively high baseline scores (SPC group mean (SD) 75.5 (17.6), control group 
74.3 (17.3)) and experienced large improvements of -21.7 and -17.8 points, respectively, to 3 
weeks, and minor additional improvements to 8 weeks. 
 
Secondary outcomes 
The separate analyses of each of the seven EORTC QLQ-C30 scales also showed no differences 
between SPC and control groups, maybe with the exception of nausea/vomiting for which the 
largest change was seen (-5.8 points; -10.3 to -1.2) favouring the SPC group (Table 3). This was 
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also the lowest p-value (0.013), close to the selected threshold (0.01). The five sensitivity analyses 
showed similar results (Table 4). 
 
Of the 297 patients, 197 (66%) had died three months after the end of data collection. Survival time 
did not differ between the two groups (SPC group median 323 days versus control group 364 days, 
p=0.16, fully adjusted analysis p=0.39) (Fig. 2).  
 








This first European randomised clinical trial of early SPC plus standard care versus standard care 
alone in advanced cancer patients with a range of diagnoses showed no clear beneficial or harmful 
effects.  There was no difference in the primary outcome (p=0.14). The 95% confidence interval (-
11.3 to +1.6 points) does not exclude the possibility of the hypothesised difference of -7.5 points 
favouring early SPC. The five sensitivity analyses showed similar results.  
 
 
Whereas our primary outcome was an unusual, patient-individualised outcome, the secondary 
outcomes were analysed ‘traditionally’, and examined each of the seven EORTC QLQ-C30 scales 
selected for the trial. Again, no significant differences (p<0.01) between groups were found, maybe	
with	the	exception	of	the	outcome nausea	and	vomiting	where	the	early	SPC	might	have	a	
beneficial	effect. Survival time was not significantly affected. 
 
    
Compared to the other trials of early SPC, DanPaCT is among the larger trials, was based on 
individual randomisation, and was conducted with high completeness of data at follow-up. 
Although we recruited patients with advanced cancer throughout the disease course, the median 
survival was about 12 months, which was similar to Temel et al’s trial.9 
 
Our trial has several strengths. The randomisation was conducted through central, stratified 
allocation by a computer-generated sequence unknown to the investigators. We stratified for 
primary need, our intervention groups seemed well randomised, and we considered stratification in 
our analyses. We conducted our analyses blinded, and missing data were handled by multiple 
imputation and sensitivity analyses. We also drew our conclusions blinded to intervention 
group.25,26  
 
How should we interpret the lack of a clear effect of early SPC in DanPaCT? One obvious reason 
could be that early SPC does not work. However, we find it premature to draw such a conclusion. 
First, although our trial reached its planned size (N=300), it is still a relatively small trial and may 
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have overlooked therapeutic benefits. Second, as discussed below, there are several aspects of our 
trial that may explain the neutral findings even if early SPC is beneficial. 
  
Possible under-treatment of the intervention group? 
Our intention was to study the effect of what seemed to us as a clinically relevant future scenario for 
improvement of palliative care, i.e., that patients with advanced cancer in oncology departments 
were regularly screened for palliative needs, and if such needs were identified, patients were 
referred to SPC. We did not request that any specific treatment guidelines or any frequency of visits 
were used in the SPC teams, as we wanted to investigate ‘usual SPC’ as offered by six of the most 
experienced teams in Denmark. 
 
The number of face-to-face contacts in the intervention group was low: only 51% (74/145) were 
seen by SPC teams more than once during the eight weeks trial period, although there were more 
frequent telephone contacts. The SPC teams in Denmark have relatively low capacity and usually 
receive patients with very complex symptoms and a short survival;2 the SPC teams may have 
perceived some DanPaCT patients as having no urgent need compared to their other patients.   
 
Should some of the patients identified via the DanPaCT screening procedure be regarded as false 
positive? Maybe ‘early SPC needs’ require a different type of intervention, e.g., a more structured 
approach with planned visits even when there are no alarming symptoms and where the content is 
structured around patient-education,10,15 coping, communication, and prognostic awareness.30 Each 
of our six SPC teams received only about 25 intervention patients, and they may not have had the 
time and attention to build up a specific approach. Temel and Zimmerman and colleagues 
conducted single centre trials, which may involve stronger and more focussed interventions.1,9 On 
the other hand, such single centre trials may have less external validity. 
 
Formalised collaboration between SPC team and oncology departments, e.g. via multidisciplinary 
conferences, may improve the impact of SPC, but this was not routinely practiced in Denmark 
while this trial was conducted. 
 
Finally, our intervention period of eight weeks was relatively short, and, as we had hoped, this 
resulted in high completeness of data at follow-up. When designing our trial we had the belief that 
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an effect of SPC would be observed within few weeks and we were keen to limit attrition in order to 
maximise the power of the trial. Our three-week assessment was chosen to secure information from 
patients who dropped out early. Temel’s initial trial was 12 weeks,9 and Zimmerman’s trial found 
most effect after four months.1 Temel’s second trial found no impact on quality of life at 12 weeks 
but at 24 weeks.13 We may have overlooked a benefit beyond eight weeks.   
 
Cross-over/ compensation in control group? 
The proportion of crossover from the control group to SPC was limited (13/152; 8.6%), but may 
have reduced the difference between groups.  
 
May some of the experienced study nurses at the oncology departments have felt a moral obligation 
to compensate for the lack of SPC? They may have encouraged patients in the control group to 
contact their oncology doctor or GP. The nurses may also have taken a good, long talk with 
distressed patients, or may have suggested contacting a psychologist or counselling. The oncology 
department staff may have made an extra effort to help disappointed patients. If such extra activity 
took place in the control group, it is a bias weakening our ability to detect an effect of the 
intervention.  
 
A related possibility is that, as this was not a cluster RCT, the oncologists may have learned from 
the palliative care consultations done with patients in the intervention group and may thus have 




Of all oncology patients screened, about 43% were above our threshold for having a need. We used 
the EORTC QLQ-C30, which is one of the most widely used and validated measures in oncology 
trials.31,32 Our choice of seven QLQ-C30 scales for screening may of course be disputed but still 
one would expect a better effect in patients with documented needs than if all patients were offered 
treatment. 
 
The scores for the remaining symptoms/problems were relatively low, indicating that the number of 
problems per patient was limited. This was the motivation for our unusual outcome: we devised the 
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patient-individualised outcome in order to address the methodological problems arising from the 
heterogeneous nature of palliative care needs: if, e.g., only 20% of the patients need additional 
treatment for pain, then even with excellent effect among these 20%, the overall effect measured on 
the pain scale is diluted by the lack of change in the 80% not treated for pain (and there might be 
insufficient power to detect a difference among the 20%). The average change on the seven QLQ-
C30 scales was -2.2 points, while the change on the primary outcome was -4.9 points. Thus, there is 
very preliminary evidence supporting the assumption that the new approach is more sensitive. Our 
combination of a new outcome with a traditional analysis of seven symptom scales selected to cover 





This RCT could not show beneficial or harmful effects of early SPC in advanced cancer patients 
with palliative care needs. These findings and their interpretations should be studied carefully by 
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Excluded after answering questionnaire (n=682) 
¨  Did not have palliative needs according to 
questionnaire (n=621) 
¨  Did not fulfill other inclusion criteria (n=54) 
¨  Died (n=7) 
 
 Eligible for randomisation (n=464) 
Randomized (n=306) Excluded after randomisation (n=9)  
¨  Withdrew consent (n=5)  
¨  Randomisation failure (n=4) 
 
True randomized (n=297) 
Allocated to control (n=152) 
¨ Received allocated intervention (n= 139) 
¨ Did not receive allocated intervention (cross-over 
patients who received SPI in the trial period) (n=13) 
 
 
Allocated to intervention (SPC) (n= 145) 
¨ Received allocated intervention (n=138) 
¨ Did not receive allocated intervention (died before 
it started or organisation failure) (n=7) 
Allocation 
Included in primary analysis (n=137) 
¨ Excluded from analysis (died) (n=15) 
Lost to follow-up (n=39) 
¨ Died (n=15) 
¨ Did not answer questionnaire (n=20) 
¨ Administrative failure (n=4) 
 
Lost to follow-up (n=32) 
¨ Died (n=15) 
¨ Did not answer questionnaire (n=9) 
¨ Administrative failure (n=8) 
 
Included in primary analysis (n=130) 




Did not participate (n=158)  
¨ Did not want to (n=124) 
¨ No reason given (n=29) 
¨ Administrative failure (n=5) 
Eligible for questionnaire (n=1,472) 
Did not answer questionnaire (n=326) 
 
Answered questionnaire (n=1,146) 
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Table 1. Baseline characteristics of 297 DanPaCT participants.  
  
Intervention 







Age <50 years 10 (7) 15 (10) 
 50 - 59 years 27 (19) 25 (16) 
 60 - 69 years 65 (45) 58 (38) 
 70 - 79 years 36 (24) 45 (29) 
 ≥80 years 7 (5) 9 (6) 
Sex Men 63 (43) 62 (41) 
 Women 82 (57) 90 (59) 
Cancer Lung 57 (39) 46 (30) 
 Digestive system 20 (14) 38 (25) 
 Breast 31 (21) 35 (23) 
 Other 37 (26) 33 (22) 
Receiving  Yes 120 (83) 122 (80) 
chemotherapy No 25 (17) 29 (19) 
 Missing 0 (0) 1 (1) 
WHO  0 23 (18) 36 (24) 
performance  1 78 (54) 79 (52) 
scorea 2 27 (19) 16 (11) 
 3 1 (1) 4 (3) 
 Missing 16 (11) 17 (11) 
Time since  <12 months 83 (57) 94 (62) 
diagnosed 12-24 months 27 (19) 20 (13) 
with stage IV >24 months 32 (22) 36 (24) 
 Missing 3(2) 2 (1) 
Education  None 26 (18) 18 (12) 
 Semi-skilled worker/short education (<1 
year) 19 (13) 19 (13) 
 Skilled worker 23 (16) 31 (20) 
 Short theoretical (1-3 years) 21 (14) 24 (16) 
 Long theoretical (>3 years) 39 (27) 44 (29) 
 Academic 9 (6) 11 (7) 
 Missing 8 (6) 5 (3) 
Centre Bispebjerg University Hospitalb 25 (17) 25 (16) 
 Copenhagen University Hospital 
Rigshospitaletb  28 (19) 23 (15) 
 Odense University Hospital 20 (14) 28 (18) 
 Vejle Hospital 29 (20) 20 (13) 
 Aarhus University Hospital 19 (13) 29 (19) 
 Herning Hospital  24 (17) 27 (18) 
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Primary needc  Physical function 12 (8) 11 (7) 
 Role function 52 (36) 54 (36) 
 Emotional function 9 (6) 13 (9) 
 Pain 19 (13) 18 (12) 
 Nausea/vomiting 5 (3) 6 (4) 
 Dyspnea 25 (17) 26 (17) 
 Lack of appetite 23 (16) 24 (16) 
a) WHO Performance Score ranges from 0 to 4, where 0=able to carry out all normal activity without 
restriction and 4= completely disabled; cannot carry on any self-care; totally confined to bed or chair. 
b) Patients for the palliative care teams at Bispebjerg and Rigshospitalet were recruited from the 
Department of Oncology, Copenhagen University Hospital Rigshospitalet. 
c) The number of patients having each primary need. The primary need was the symptom or problem out of 




Table 2. Face-to-face and telephone contacts with specialised palliative care during the eight-weeks 
trial period in DanPaCT. 
 
 Intervention group (N=145)  Control group (N=152) 
Number of contacts Face-to-face Telephone  Face-to-face Telephone 
None 7* 29  139 143 
1 64  27  9 4 
2  32 22  3 2 
3-4  25 40  0 2 
5 or more 17 27  1 1 





Table 3. Results of the main analysis of the primary1 and secondary outcomes measured by the EORTC QLQ-C30. Multiple linear regression was used. 
A negative mean weighted change value in the primary outcome and in symptom scales indicates a larger symptom reduction in the intervention group 
than in the control group. The opposite is the case for the function scales. 













 Mean weighted   
change2 (95% CI) 
 
p 
Primary outcome1 (range 0-100, worst score 100)       
 75.5 (22.7) 53.8 (29.7) 50.7 (29.6)  74.3 (17.3) 56.5 (27.5) 55.4 (29.9)  -4.9 (-11.3; 1.6) 0.14 
Secondary outcomes  
Function scales (range 0-100, worst score 0) 
Physical function 57.5 (19.6) 59.1 (22.8) 57.6 (22.3)  58.8 (19.3) 60.2 (21.0) 59.9(22.5)  -0.4 (-4.0; 3.2) 0.84 
Role function 36.8 (25.0) 42.7 (29.7) 46.9 (30.4)  41.8 (27.0) 47.0 (27.9) 45.7 (30.4)  2.1 (-3.9; 8.1) 0.48 
Emotional function 67.8 (22.4) 69.6 (23.1) 73.0 (21.4)  66.7 (22.1) 72.2 (22.4) 70.1 (22.7)  -1.6 (-5.7; 2.5) 0.45 
Symptom scales (range 0-100, worst score 100) 
Pain 35.5 (30.2) 29.4 (28.7) 31.4 (30.0)  34.2 (26.0) 30.5 (27.3) 35.0 (30.8)  -3.4 (-9.5; 2.6) 0.27 
Dyspnea 41.6 (33.8) 35.4 (35.2) 36.5 (32.5)  39.8 (33.4) 38.0 (32.7) 38.7 (31.0)  -4.2 (-10.6; 2.3) 0.20 
Nausea/vomiting 17.1 (24.1) 9.5 (15.4) 8.9 (15.6)  17.6 (18.1) 15.2 (18.8) 14.8 (22.6)  -5.8 (-10.3; -1.2) 0.013 
Lack of appetite 30.5 (34.7) 24.8 (30.6) 22.6 (29.3)  38.0 (33.5) 33.8 (32.0) 31.7 (35.4)  -2.0 (-8.9; 4.9) 0.57 
1) The primary outcome was patient-individualised (for each patient, the scale, out of the seven listed here, with the score representing the highest 
symptomatology was chosen as primary outcome). It was scored with 100 as the worst possible score. 
2) Mean weighted change: the difference in the area under the curve (AUC) converted to the original QLQ-C30 scale (0-100).   
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Table 4. Results from the five sensitivity analyses in DanPaCT, compared to the results of the primary analysis. The sensitivity analyses are described in 
the text. The mean weighted change (MWC) and the p values are shown except for the repeated measures analysis, where MWC is not applicable. A 
negative MWC value in the primary outcome and in symptom scales indicates a larger symptom reduction in the intervention group than in the control 
group. The opposite is the case for the function scales. 
 Primary analysis  Sensitivity analyses 








MWC p  MWC p  MWC p  NA p  MWC p  MWC p 
Primary outcome -4.9  0.14     -3.8 0.28   0.12  -3.2 0.34  -4.3 0.20 
Function scales (range 0-100, worst score 0)              
Physical function -0.4 0.84     -1.0 0.59   0.79  -1.4 0.42  -0.9 0.61 
Role function 2.1 0.48  1.9 0.53  -0.2 0.95   0.37  -0.2 0.94  2.3 0.45 
Emotional function -1.6 0.45     -1.9 0.34   0.71  -0.7 0.72  -1.7 0.37 
Symptom scales (range 0-100, worst score 100)              
Pain -3.4 0.27     -2.2 0.50   0.18  -1.5 0.65  -1.2 0.70 
Dyspnoea -4.2 0.20  -4.7 0.16  -3.5 0.31   0.17  -4.1 0.21  -4.1 0.20 
Nausea /vomiting -5.8 0.013     -6.3 0.0075   0.0115  -5.4 0.0178  -4.7 0.044 
Lack of appetite -2.0 0.57     -3.6 0.30   0.52  -1.9 0.59  -2.4 0.49 
1) Additional covariates were included in the fully adjusted analysis if they were significantly associated with the outcome; however, this was not 
always the case, and therefore, the results are only shown when they differ from the primary analysis.
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